June 2008. Volume 4. Number 2

La utilización de terapia combinada de PegInteferón más Ribavirina podría limitar la progresión de Hepatitis C crónica en niños

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Jara P, Hierro L, De la Vega A, Díaz C, Camarena C, Frauca E, et al. Efficacy and safety of peginterferon-α2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J. 2008;27:142-8
Reviewers: Carvajal Encina F1, Bonillo Perales A2.
1UCIN Hospital de La Serena y Escuela de Medicina Universidad Católica del Norte. Coquimbo. Chile.
2 Unidad de Cuidados Intensivos Pediátricos. Hospital Torrecárdenas. Almerí­a . España.
Correspondence: Fernando Carvajal Encina. Email: fcarvajal@ucn.cl
Reception date: 06/05/2008
Acceptance date: 25/05/2008
Publication date: 01/06/2010

Abstract

How to cite this article

Carvajal Encina F, Bonillo Perales A. La utilización de terapia combinada de PegInteferón más Ribavirina podría limitar la progresión de Hepatitis C crónica en niños. Evid Pediatr. 2008;4:40.

AVC | Critically appraised articles

Jara P, Hierro L, De la Vega A, Díaz C, Camarena C, Frauca E, et al. Efficacy and safety of peginterferon-α2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J. 2008;27:142-8
Reviewers: Carvajal Encina F1, Bonillo Perales A2.
1UCIN Hospital de La Serena y Escuela de Medicina Universidad Católica del Norte. Coquimbo. Chile.
2 Unidad de Cuidados Intensivos Pediátricos. Hospital Torrecárdenas. Almerí­a . España.
Correspondence: Fernando Carvajal Encina. Email: fcarvajal@ucn.cl
Reception date: 06/05/2008
Acceptance date: 25/05/2008
Publication date: 01/06/2010

How to cite this article

Carvajal Encina F, Bonillo Perales A. La utilización de terapia combinada de PegInteferón más Ribavirina podría limitar la progresión de Hepatitis C crónica en niños. Evid Pediatr. 2008;4:40.

References

  1. Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chornic hepatitis C. Hepatology. 2005;41:1013-8.
  2. Lidsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoeps J, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395-403.
  3. Manns MP, McHutchison JG, Gordon SC, Urstgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribarivin compared with interferon alfa-2b plus ribavirin for inicial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-67.
  4. Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, et al. Cost-effectiveness of combination peginterferon alpfa-2a and ribavirin compared with interferon alfa-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol. 2004;1490-6.
  5. González-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology. 2005;42:1010-8.
  6. Jacobson KR, Murray K, Zellos A, Schwarz KB. An análisis of Publisher trial of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2002;34:52-8.
01/06/2010

Linked Comment